
SUPPLEMENTAL MATERIAL


Supplemental Figure 1.

Survival by RHF groups for patients who are alive at 1 month post-implant according to type of RHF manifestation




Supplemental Figure 2. Panel a

Survival by RHF groups for patients who are alive at 6 months post implant and have completed both 3- and 6-month follow-up according to subtype of RHF



Supplemental Figure 2. Panel b

Survival by RHF groups for patients who are alive at 12 months post implant and have completed 3-, 6- and 12-month follow-up according to subtype of RHF



Supplemental figure legends

Supplemental Figure 1. Survival by RHF groups for patients who are alive at 1 month post-implant according to type of RHF manifestation. Event was death censored at transplant, recovery or exchange.

Supplemental Figure 2. Panel A. Survival by RHF groups for patients who are alive at 6 months post implant and have completed both 3- and 6-month follow-up according to subtype of RHF. Panel B. Survival by RHF groups for patients who are alive at 12 months post implant and have completed 3-, 6- and 12-month follow-up according to subtype of RHF. Event was death censored at transplant, recovery or exchange.

Supplemental Table 1. Potential Covariates for Modeling

Age History of Alcohol Abuse
Married Pulmonary Vascular Disease

Female History of Stroke

White History of Noncompliance

College Previous Atrial Valve Repair/Replacement
Hispanic Previous Mitral Valve Repair/Replacement
INR Previous Tricuspid Valve Repair/Replacement

Sodium Previous Cardiac Surgery

BUN Left Ventricular Ejection Fraction < 20%

SGOT/AST Cardiac Index

Creatinine Elevated Systolic Blood Pressure > 120 mmHg

Bilirubin Pulmonary Wedge Pressure
Albumin Diastolic Blood Pressure

WBC Left Ventricular End Diastolic Diameter

SGPT/ALT Cardiac Output

LDH Pulmonary Vascular Resistance

Right Ventricular Ejection Fraction - Pulmonary Systolic Pressure

Ascites Mitral Regurgitation (Moderate/Severe)

CV Pressure Pulmonary Diastolic Pressure

Inotropes Tricuspid Regurgitation (Moderate/Severe)

Device Strategy Atrial Regurgitation (Moderate/Severe)

Left Ventricular Assist Device - Centrifugal

Flow

TCS Modifier Concomitant Atrial Valve Repair/Replacement
Arrhythmia Modifier Concomitant Mitral Valve Repair/Replacement

NYHA 4 Concomitant Tricuspid Valve

Repair/Replacement

Ventilator Concomitant Cardiac Surgery ICD Coronary Artery Disease

Dialysis RHF reported at 1 month post implant

IABP Pump related infection within 3m post implant Warfarin Driveline infection within 3m post-implant

Visual Analog Scale Sepsis within 3m post-implant

Mobility Issues Positive blood cultures within 3m post-implant

Self-care Issues Other infections within 3m post-implant

BSA BMI

Blood Type O

Patient Profile

Pulmonary Hypertension

Diabetes

Supplemental Table 2. Risk Adjusted Survival by RHF groups for patients who are alive at 3 months post-implant and have completed both 1- and 3-month follow-up according to subtype of RHF. Cox proportional hazard model.

Effect	Hazard Ratio	P-value
Persistent RHF	2.797	<0.0001
Denovo RHF	1.479	0.0101
Resolved RHF	1.282	0.0053
Positive Blood Cultures within 3m Post Implant	2.043	<0.0001
Previous Cardiac Surgeries	1.320	0.0001
BUN (mg/dL) 5-unit change	1.025	0.0077
Age At Implant	1.024	<0.0001
VAS: Own Health State	0.995	0.0116
Albumin (g/dL)	0.853	0.0045
Blood Type O	0.800	0.0011
Married	0.770	0.0004

Potential Covariates: Supplemental Table 1

Supplemental Table 3. Risk Adjusted Survival by RHF groups for patients who are alive at 3 months post-implant and have completed both 1- and 3-month follow-up according to subtype of RHF. Completing risk model.

Effect	Hazard Ratio	P-value
Persistent RHF	2.600	<0.0001
Denovo RHF	1.480	0.0122
Resolved RHF	1.300	0.0026
Positive Blood Cultures within 3m Post Implant	1.833	0.0007
Destination Therapy	1.634	<0.0001
Previous Cardiac Surgeries	1.347	<0.0001
Left Ventricle Assist Device - Centrifugal	1.229	0.0338
Age At Implant	1.023	<0.0001
BUN (mg/dL) 5-unit change	1.022	0.0173
LVEF < 20% (severe) (0,1)	0.856	0.0342
Albumin (g/dL)	0.818	0.0004
Hispanic	0.642	0.0137

Potential Covariates: Supplemental Table 1